New award for alendronate tablets with marlex pharmaceuticals, INC. Period of performance is may 21ST, 2021 to may 20TH, 2022 with four one-year options.
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79721D0023
- Awardee
-
Marlex Pharmaceuticals Inc. UEI VSSNJEFMPLB3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Alendronate Tablets Pre-Solicitation · 36E79721R0010 · Posted Dec 14, 2020
- 6505--Alendronate Tablets Award Effective 5/21/2021 - 5/20/2022 Award Notice · Posted Mar 23, 2021
- 6505--Alendronate Tablets Solicitation · Posted Jan 14, 2021
- Last date to order 100% complete
- IDV ceiling
- $5,764,212.00
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Marlex Pharmaceuticals Inc., a minority-owned and self-certified small disadvantaged business manufacturer of generic pharmaceutical and medical products.
The $5.7 million contract covers the supply of alendronate tablets in different sizes to support the medical needs of the VA, Bureau of Prisons, and Indian Health Service. The contract has a one-year base period from May 2021 to May 2022, with four one-year option periods, for a total potential duration of 5 years. As an IDC, this contract allows for the issuance of individual delivery orders against the established terms and conditions. Marlex Pharmaceuticals was selected as the sole awardee through a competitive procurement process without any set-aside requirements. The contract aims to ensure an uninterrupted supply of this essential generic medication to federal healthcare programs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79721D0023?
36E79721D0023 was awarded to Marlex Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on May 21, 2021.
How much is contract 36E79721D0023 worth?
36E79721D0023's own ceiling is $5,764,212.
Who can order from contract 36E79721D0023?
36E79721D0023 is a single award indefinite delivery contract.
Was contract 36E79721D0023 competed?
The extent of competition for 36E79721D0023 was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV